Lifeward (LFWD)
NASDAQ:LFWD
Top Page
Lifeward
(NASDAQ:LFWD)
Select Model
Select Model
Rating:46Neutral
Price Target:
$6.50
â–¼(-1.07% Downside)
Action:ReiteratedDate:04/01/26
The score is held down primarily by weak financial performance driven by large ongoing losses and sustained cash burn, with additional pressure from a negative earnings-based valuation signal (negative P/E). Technicals are mixed but lean bearish due to price trading below longer-term moving averages. Corporate events provide some support via restored Nasdaq compliance and new financing/M&A activity, but the benefits are tempered by dilution and expensive secured funding.
Positive Factors
Strategic acquisition and financing
Closing the Oratech acquisition and accompanying private financing is a structural shift: it broadens Lifeward’s technology base and creates revenue‑sharing ties to its ReWalk personal product while providing near‑term capital to integrate assets and pursue commercialization, strengthening long‑term growth optionality.
Negative Factors
Persistent cash burn
Consistent, sizable operating and free cash outflows mean the business relies on external financing to continue operations. This persistent cash burn reduces runway, constrains discretionary investment in commercialization or R&D, and makes the company sensitive to capital‑market access over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic acquisition and financing
Closing the Oratech acquisition and accompanying private financing is a structural shift: it broadens Lifeward’s technology base and creates revenue‑sharing ties to its ReWalk personal product while providing near‑term capital to integrate assets and pursue commercialization, strengthening long‑term growth optionality.
Read all positive factors
Lifeward (LFWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.04M
Dividend YieldN/A
Average Volume (3M)316.99K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth-2.02%
EPS Growth-32.93%
CountryUS
Employees80
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-2.85
Shares Outstanding1,528,222
10 Day Avg. Volume318,606
30 Day Avg. Volume316,993
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)9.55
Price to Sales (P/S)3.64
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue0.43
Enterprise Value/Gross Profit1.12
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$10.00Price Target Upside52.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.76
Revenue Forecast (FY)$42.79M
Lifeward Business Overview & Revenue Model
Company Description
Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand up...
How the Company Makes Money
Lifeward generates revenue primarily by selling its ReWalk exoskeleton systems and associated accessories to customers in clinical/rehabilitation and personal-use settings, with revenue recognized based on product sales and deliveries. The company...
Lifeward Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The earnings call for Lifeward Ltd. highlighted significant operational improvements and strategic expansions, particularly in the ReWalk product line and European market access. However, challenges remain with declining revenue in the ATLAS G product line and increased operating expenses. The company is optimistic about its transformation and future growth, bolstered by operational efficiencies and financial backing.Positive Updates
Record Quarter for ReWalk Placements
Lifeward Ltd. delivered another record quarter for ReWalk placements for Medicare beneficiaries, marking the second consecutive record since CMS established their fee schedule in April 2024.
Negative Updates
Decline in ATLAS G Product Revenue
Revenue from the ATLAS G product and services was $3.1 million in Q3 2025, down from $3.6 million in Q3 2024, primarily due to timing factors and quarterly revenue mix.
Read all updates
Q3-2025 Updates
Positive
Negative
Record Quarter for ReWalk Placements
Lifeward Ltd. delivered another record quarter for ReWalk placements for Medicare beneficiaries, marking the second consecutive record since CMS established their fee schedule in April 2024.
Read all positive updates
Company Guidance
During the Lifeward Ltd. Third Quarter 2025 Earnings Conference Call, the company provided financial guidance reaffirming full-year 2025 revenue expectations between $24 million and $26 million, and a projected non-GAAP net loss ranging from $12 million to $14 million. The CFO, Almog Adar, highlighted a 16% reduction in quarterly cash burn and a 27% reduction in non-GAAP operating loss compared to the previous year. Revenue for Q3 2025 was $6.2 million, an increase from $6.1 million in 2024, with a notable 24% increase in sales of traditional products like the ReWalk personal exoskeleton. Additionally, Lifeward Ltd. ended the quarter with $2 million in cash, supported by a $3 million loan agreement with Oramed, and anticipates further reductions in operating loss as sales volumes grow.Lifeward Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.03M | 25.66M | 13.85M | 5.51M | 5.97M |
| Gross Profit | 8.43M | 8.22M | 4.45M | 1.91M | 2.90M |
| EBITDA | -16.56M | -24.93M | -21.77M | -18.90M | -12.39M |
| Net Income | -19.91M | -28.94M | -22.13M | -19.57M | -12.74M |
Balance Sheet | |||||
| Total Assets | 22.90M | 30.49M | 63.19M | 74.24M | 94.75M |
| Cash, Cash Equivalents and Short-Term Investments | 2.17M | 6.94M | 28.08M | 67.90M | 88.34M |
| Total Debt | 1.58M | 880.00K | 1.90M | 897.00K | 1.06M |
| Total Liabilities | 14.49M | 11.64M | 16.68M | 6.07M | 5.37M |
| Stockholders Equity | 8.41M | 18.85M | 46.51M | 68.17M | 89.38M |
Cash Flow | |||||
| Free Cash Flow | -16.83M | -21.72M | -20.75M | -17.92M | -11.52M |
| Operating Cash Flow | -16.83M | -21.72M | -20.67M | -17.89M | -11.47M |
| Investing Cash Flow | -16.00K | 0.00 | -18.15M | -25.00K | -47.00K |
| Financing Cash Flow | 12.20M | 0.00 | -992.00K | -2.50M | 79.51M |
Lifeward Technical Analysis
Negative
6.57
Price Trends
6.50
Positive
7.10
Negative
7.56
Negative
Market Momentum
<0.01
Positive
49.36
Neutral
57.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Negative. The current price of 6.57 is below the 20-day moving average (MA) of 6.69, above the 50-day MA of 6.50, and below the 200-day MA of 7.56, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.36 is Neutral, neither overbought nor oversold. The STOCH value of 57.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFWD.
Lifeward Risk Analysis
Lifeward disclosed 43 risk factors in its most recent earnings report. Lifeward reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lifeward Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $6.43M | -1.24 | -84.30% | ― | -20.05% | 41.89% | |
46 Neutral | $10.04M | -4.03 | -127.95% | ― | -2.02% | -32.93% | |
45 Neutral | $8.30M | -0.21 | -279.58% | ― | 147.74% | 73.23% | |
45 Neutral | $58.98M | -1.01 | 1.02% | ― | -99.28% | -46.17% | |
43 Neutral | $4.94M | -0.07 | -70.27% | ― | -87.84% | 29.16% | |
42 Neutral | $20.93K | >-0.01 | ― | ― | ― | ― |
* Healthcare Sector Average
LFWD
Lifeward
6.57
-10.71
-61.98%
BMRA
Biomerica
2.13
-2.29
-51.81%
CODX
Co-Diagnostics
1.37
-9.50
-87.40%
XAIR
Beyond Air
0.79
-3.89
-83.16%
PAVM
PAVmed
9.24
-12.37
-57.24%
DHAI
DIH Holdings US, Inc Class A
0.01
-3.76
-99.73%
Lifeward Corporate Events
Executive/Board ChangesDelistings and Listing ChangesRegulatory Filings and Compliance
Lifeward Restores Nasdaq Compliance With Audit Committee Changes
Positive
Mar 31, 2026
Lifeward Ltd. had previously fallen out of compliance with Nasdaq Listing Rule 5605(c)(2)(A) after director Hadar Levy resigned from its board and audit committee, leaving the committee with fewer than the required three members. On March 30, 2026...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Lifeward Completes Oratech Acquisition and Secures Private Financing
Positive
Mar 25, 2026
On March 25, 2026, Lifeward completed its previously announced acquisition of Oratech Pharma from Oramed, issuing 2,256,476 ordinary shares and pre-funded warrants, along with additional transaction warrants and a revenue-sharing arrangement tied ...
Executive/Board ChangesDelistings and Listing ChangesRegulatory Filings and Compliance
Lifeward Faces Nasdaq Audit Committee Compliance Challenge
Negative
Mar 20, 2026
On March 17, 2026, Lifeward Ltd. disclosed it had received a notice from Nasdaq’s Listing Qualifications Department that the company no longer complies with Listing Rule 5605(c)(2)(A), after director Hadar Levy’s resignation reduced it...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Lifeward Shareholders Approve Oratech Deal and Governance Changes
Positive
Mar 13, 2026
Lifeward Ltd. reported that 7,252,783 ordinary shares, representing about 39.7% of its outstanding shares as of January 20, 2026, were present or voted at its March 12, 2026 extraordinary general meeting, establishing quorum and enabling sharehold...
Delistings and Listing ChangesRegulatory Filings and Compliance
Lifeward Regains Compliance With Nasdaq Minimum Bid Rule
Positive
Mar 11, 2026
On March 10, 2026, Lifeward Ltd. announced it had regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum closing bid price of at least $1.00 for 10 consecutive business days, from February 24 to Marc...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Lifeward Executes Reverse Share Split to Maintain Listing
Neutral
Mar 2, 2026
On February 24, 2026, Lifeward Ltd. implemented a 1-for-12 reverse share split of its ordinary shares following shareholder approval at an extraordinary general meeting held on January 6, 2026 and subsequent board finance committee decisions in la...
Executive/Board Changes
Lifeward Announces Routine Board Change with Director Resignation
Neutral
Feb 27, 2026
On February 24, 2026, Lifeward Ltd. announced that Class I director Hadar Levy resigned from the board, effective the same day, in a move the company said was not related to any disagreement over operations, policies or practices. The board expres...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Lifeward Expands IP Portfolio With Skelable Acquisition Deal
Positive
Feb 25, 2026
On February 19, 2026, Lifeward Ltd. entered into an Intellectual Property Assignment and Technology Transfer Agreement with Israeli company Skelable Ltd., under which Lifeward will acquire specified intellectual property, related technology assets...
Private Placements and Financing
Lifeward Enters High-Interest Secured Promissory Note Financing
Negative
Feb 19, 2026
On February 12, 2026, Lifeward Ltd. entered into a new secured promissory note with Oramed Pharmaceuticals, Inc. for an initial principal of $525,000, potentially rising by an additional $975,000 by mutual consent. The note, secured by a lien on t...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Lifeward Granted Nasdaq Extension to Regain Listing Compliance
Negative
Feb 9, 2026
On August 5, 2025, Lifeward Ltd. received notice from Nasdaq that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days, putting the company out of compliance with Nasdaq’s listing requirements. After faili...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Lifeward Plans Shareholder Vote on Oratech Acquisition Deal
Positive
Jan 28, 2026
Lifeward has called an Extraordinary General Meeting of shareholders for March 12, 2026, in Hudson, Massachusetts, to vote on several corporate actions tied to a major strategic transaction and related governance and compensation matters. Sharehol...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Lifeward Forms Strategic Partnership and Financing Deal with Oramed
Positive
Jan 13, 2026
On January 12–13, 2026, Lifeward entered into a transformative strategic partnership and share purchase agreement with Oramed Pharmaceuticals under which Lifeward will acquire Oramed’s clinical-stage Protein Oral Delivery (POD™) ...
Business Operations and StrategyShareholder MeetingsStock Split
Lifeward Shareholders Approve Capital Structure and Split Flexibility
Positive
Jan 6, 2026
On January 6, 2026, Lifeward Ltd. held an Extraordinary General Meeting of Shareholders at which 41.7% of its outstanding ordinary shares were represented, constituting a quorum. Shareholders approved three key amendments to the company’s Ar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.